Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

97 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
CDK inhibition and cancer therapy.
Garrett MD, Fattaey A. Garrett MD, et al. Curr Opin Genet Dev. 1999 Feb;9(1):104-11. doi: 10.1016/s0959-437x(99)80015-x. Curr Opin Genet Dev. 1999. PMID: 10072351 Review.
New functional activities for the p21 family of CDK inhibitors.
LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E. LaBaer J, et al. Genes Dev. 1997 Apr 1;11(7):847-62. doi: 10.1101/gad.11.7.847. Genes Dev. 1997. PMID: 9106657
Clinical anticancer drug development: targeting the cyclin-dependent kinases.
Benson C, Kaye S, Workman P, Garrett M, Walton M, de Bono J. Benson C, et al. Br J Cancer. 2005 Jan 17;92(1):7-12. doi: 10.1038/sj.bjc.6602229. Br J Cancer. 2005. PMID: 15558073 Free PMC article. Review.
Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.
Barvian M, Boschelli DH, Cossrow J, Dobrusin E, Fattaey A, Fritsch A, Fry D, Harvey P, Keller P, Garrett M, La F, Leopold W, McNamara D, Quin M, Trumpp-Kallmeyer S, Toogood P, Wu Z, Zhang E. Barvian M, et al. J Med Chem. 2000 Nov 30;43(24):4606-16. doi: 10.1021/jm000271k. J Med Chem. 2000. PMID: 11101352
The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.
Whittaker SR, Walton MI, Garrett MD, Workman P. Whittaker SR, et al. Cancer Res. 2004 Jan 1;64(1):262-72. doi: 10.1158/0008-5472.can-03-0110. Cancer Res. 2004. PMID: 14729633
Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Yap TA, et al. Curr Opin Pharmacol. 2008 Aug;8(4):393-412. doi: 10.1016/j.coph.2008.08.004. Epub 2008 Aug 27. Curr Opin Pharmacol. 2008. PMID: 18721898 Review.
Cell cycle-regulated phosphorylation of p220(NPAT) by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription.
Ma T, Van Tine BA, Wei Y, Garrett MD, Nelson D, Adams PD, Wang J, Qin J, Chow LT, Harper JW. Ma T, et al. Genes Dev. 2000 Sep 15;14(18):2298-313. doi: 10.1101/gad.829500. Genes Dev. 2000. PMID: 10995387 Free PMC article.
Optimising measles virus-guided radiovirotherapy with external beam radiotherapy and specific checkpoint kinase 1 inhibition.
Touchefeu Y, Khan AA, Borst G, Zaidi SH, McLaughlin M, Roulstone V, Mansfield D, Kyula J, Pencavel T, Karapanagiotou EM, Clayton J, Federspiel MJ, Russell SJ, Garrett M, Collins I, Harrington KJ. Touchefeu Y, et al. Radiother Oncol. 2013 Jul;108(1):24-31. doi: 10.1016/j.radonc.2013.05.036. Epub 2013 Jul 9. Radiother Oncol. 2013. PMID: 23849174
The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis.
Whittaker SR, Te Poele RH, Chan F, Linardopoulos S, Walton MI, Garrett MD, Workman P. Whittaker SR, et al. Cell Cycle. 2007 Dec 15;6(24):3114-31. doi: 10.4161/cc.6.24.5142. Epub 2007 Oct 5. Cell Cycle. 2007. PMID: 18075315
97 results
Jump to page
Feedback